TNPSC Thervupettagam

HGCO19

April 17 , 2021 1307 days 891 0
  • An additional government funding has been received by India’s mRNA-based Covid-19 vaccine candidate-HGCO19 for its clinical studies.
  • This funding has been awarded under the ‘Mission Covid Suraksha’.
  • It has been developed by Pune-based biotechnology company Gennova Biopharmaceuticals in collaboration with HDT Biotech Corporation, USA.

Leave a Reply

Your Comment is awaiting moderation.

Your email address will not be published. Required fields are marked *

Categories